The poly (ADP-ribose) polymerase inhibitor olaparib attenuates established pulmonary fibrosis in a large animal model
Abstract Background Poly (ADP‒ribose) polymerase (PARP) is a constitutive enzyme involved in regulating various biological processes in health and disease. In the present study, we investigated the role of PARP1 in pulmonary fibrosis and assessed the efficacy of a clinically approved PARP inhibitor,...
Saved in:
| Main Authors: | Habtamu B. Derseh, Andrew N. Davies, Alarna Young, Sylvie Bischof, Joseph Pelle, David Rudd, Michelle McIntosh, David Piedrafita, Robert J. Bischof |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-08-01
|
| Series: | BMC Pulmonary Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12890-025-03803-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Identification and Characterization of Novel Inhibitors of Human Poly(ADP-Ribose) Polymerase-1
by: Ibrahim Morgan, et al.
Published: (2025-06-01) -
Experience in the use of olaparib poly (ADP-ribose) polymerase inhibitors in maintenance therapy of BRCA-associated ovarian cancer
by: V. N. Zhurman, et al.
Published: (2023-02-01) -
The role of Poly-ADP ribose polymerase (PARP) enzymes in chemotherapy-induced cognitive impairments – parallels with other neurodegenerative disorders
by: Dahlia A. Ordaz, et al.
Published: (2025-06-01) -
Clinical Outcomes of Poly(ADP–Ribose) Polymerase Inhibitors as Maintenance Therapy in Patients with Ovarian Cancer in the Southeastern Region of Korea
by: Hyeong In Ha, et al.
Published: (2024-10-01) -
Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance
by: Li‐Min Wang, et al.
Published: (2023-01-01)